Comparison of Clinical Outcomes Among Users of Oral and Transdermal Estrogen Therapy in the Women's Health Initiative Observational Study

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2017 Jul 12

PMID 28697036

Citations 7

Authors

Carolyn J Crandall

Kathleen M Hovey

Christopher Andrews

Jane A Cauley

Marcia Stefanick

Chrisandra Shufelt

Ross L Prentice

Andrew M Kaunitz

Charles Eaton

Jean Wactawski-Wende

JoAnn E Manson

Affiliations

Soon will be listed here.

Abstract

Objective: To examine associations of estrogen preparations with an index of health risks versus benefits.

Methods: Using data from 45,112 participants of the Women's Health Initiative Observational Study (average follow-up 5.5 years), we examined associations of estrogen type and oral conjugated equine estrogen (CEE) dose with time to first global index event (GIE), defined as coronary heart disease, breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death.

Results: Oral CEE less than 0.625 mg/d + progestogen (P) users had a lower risk of a GIE (adjusted hazard ratio 0.74, 95% confidence interval 0.56-0.97) than oral CEE 0.625 mg/d + P users. GIE risk in oral CEE 0.625 mg/d + P users was greater with at least 5-year use (adjusted hazard ratio 1.22, 95% confidence interval 1.06-1.41) than with less than 5-year use. In women with prior hysterectomy, compared with women taking oral CEE 0.625 mg/d for less than 5 years, GIE risk was similar with oral CEE below 0.625 mg/d, oral estradiol (E2), and transdermal E2, whether used for less than 5 years or for at least 5 years. There was no difference in GIE risk between users of the following: oral CEE + P versus oral E2 + P; oral CEE + P versus transdermal E2 + P; oral E2 + P versus transdermal E2 + P. Findings were similar among women with hysterectomy taking estrogen alone.

Conclusions: The summary index of risks versus benefits was similar for oral CEE versus oral or transdermal E2-containing regimens. CEE + P containing less than 0.625 mg/d of CEE (vs 0.625 mg/d) for less than 5 years appeared safer.

Citing Articles

Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis.

Na Z, Wei W, Xu Y, Li D, Yin B, Gu W Open Life Sci. 2023; 18(1):20220759.

PMID: 38152576 PMC: 10752002. DOI: 10.1515/biol-2022-0759.

The Potential Therapeutic Effects of Platelet-Derived Biomaterials on Osteoporosis: A Comprehensive Review of Current Evidence.

Amiri M, Farshidfar N, Miron R, Dziedzic A, Hamedani S, Daneshi S Int J Biomater. 2023; 2023:9980349.

PMID: 38098766 PMC: 10721351. DOI: 10.1155/2023/9980349.

A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.

Thurman A, Hull M, Stuckey B, Hatheway J, Zack N, Mauck C Menopause. 2023; 30(8):817-823.

PMID: 37339390 PMC: 10389193. DOI: 10.1097/GME.0000000000002210.

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?.

Cho L, Kaunitz A, Faubion S, Hayes S, Lau E, Pristera N Circulation. 2023; 147(7):597-610.

PMID: 36780393 PMC: 10708894. DOI: 10.1161/CIRCULATIONAHA.122.061559.

The clinician's guide to prevention and treatment of osteoporosis.

LeBoff M, Greenspan S, Insogna K, Lewiecki E, Saag K, Singer A Osteoporos Int. 2022; 33(10):2049-2102.

PMID: 35478046 PMC: 9546973. DOI: 10.1007/s00198-021-05900-y.

References

Bergendal A, Kieler H, Sundstrom A, Linden Hirschberg A, Kocoska-Maras L . Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause. 2016; 23(6):593-9. DOI: 10.1097/GME.0000000000000611. View

. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013; 121(4):887-890. DOI: 10.1097/01.AOG.0000428645.90795.d9. View

Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7):840-5. DOI: 10.1161/CIRCULATIONAHA.106.642280. View

Opatrny L, DellAniello S, Assouline S, Suissa S . Hormone replacement therapy use and variations in the risk of breast cancer. BJOG. 2007; 115(2):169-75. DOI: 10.1111/j.1471-0528.2007.01520.x. View

Renoux C, DellAniello S, Garbe E, Suissa S . Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010; 340:c2519. DOI: 10.1136/bmj.c2519. View

Lyytinen H, Pukkala E, Ylikorkala O . Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2008; 113(1):65-73. DOI: 10.1097/AOG.0b013e31818e8cd6. View

Marjoribanks J, Farquhar C, Roberts H, Lethaby A . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012; (7):CD004143. DOI: 10.1002/14651858.CD004143.pub4. View

Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-77. DOI: 10.1001/jama.297.13.1465. View

Canonico M, Oger E, Conard J, Meyer G, Levesque H, Trillot N . Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006; 4(6):1259-65. DOI: 10.1111/j.1538-7836.2006.01933.x. View

10.

. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19(1):61-109. DOI: 10.1016/s0197-2456(97)00078-0. View

11.

Simon J, Laliberte F, Duh M, Pilon D, Kahler K, Nyirady J . Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016; 23(6):600-10. DOI: 10.1097/GME.0000000000000590. View

12.

Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F . Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 128(1):144-56. DOI: 10.1002/ijc.25314. View

13.

Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81(24):1879-86. DOI: 10.1093/jnci/81.24.1879. View

14.

Laliberte F, Dea K, Duh M, Kahler K, Rolli M, Lefebvre P . Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2011; 18(10):1052-9. DOI: 10.1097/gme.0b013e3182175e5c. View

15.

Lyytinen H, Dyba T, Pukkala E, Ylikorkala O . Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland. Int J Cancer. 2009; 127(1):185-9. DOI: 10.1002/ijc.24996. View

16.

Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-12. DOI: 10.1001/jama.291.14.1701. View

17.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

18.

Espie M, Daures J, Chevallier T, Mares P, Micheletti M, de Reilhac P . Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007; 23(7):391-7. DOI: 10.1080/09513590701382104. View

19.

Langer R, White E, Lewis C, Kotchen J, Hendrix S, Trevisan M . The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003; 13(9 Suppl):S107-21. DOI: 10.1016/s1047-2797(03)00047-4. View

20.

Mohammed K, Abu Dabrh A, Benkhadra K, Al Nofal A, Leon B, Prokop L . Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015; 100(11):4012-20. DOI: 10.1210/jc.2015-2237. View